MAIA Logo

Maia Biotechnology Inc. (MAIA) Stock Forecast & Price Prediction

Live MAIA Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$1.87

+0.00 (0.00%)

12 Month Price Forecast For MAIA

$1.87
Current Price
$49.18M
Market Cap
1 Ratings
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MAIA Price Forecasts

+648.7%
To High Target of $14.00
+575.1%
To Median Target of $12.63
+501.6%
To Low Target of $11.25

MAIA Price Momentum

-1.6%
1 Week Change
-7.4%
1 Month Change
+19.9%
1 Year Change
-5.6%
Year-to-Date Change
-68.8%
From 52W High of $5.99
+50.8%
From 52W Low of $1.24

๐Ÿค” Considering MAIA (MAIA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 16, 2025 5:02 AM UTC

MAIA Analyst Ratings & Price Targets

Based on our analysis of 1 Wall Street analyst, MAIA has a bullish consensus with a median price target of $12.63 (ranging from $11.25 to $14.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.87, the median forecast implies a 575.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Robert LeBoyer at Noble Capital Markets, projecting a 648.7% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MAIA Analyst Consensus

1
Buy
0
Hold
0
Sell

MAIA Price Target Range

Low
$11.25
Average
$12.63
High
$14.00
Current: $1.87

Latest MAIA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MAIA.

Date Firm Analyst Rating Change Price Target
Feb 21, 2023 Noble Capital Markets Robert LeBoyer Outperform Initiates $14.00

Stocks Similar to Maia Biotechnology Inc.

The following stocks are similar to MAIA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Maia Biotechnology Inc. (MAIA) Financial Data

Maia Biotechnology Inc. has a market capitalization of $49.18M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -1,188.2%.

Valuation Metrics

Market Cap $49.18M
Enterprise Value $38.68M
P/E Ratio -1.3x
PEG Ratio -1.2x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +18.3%
Current Ratio 2.6x
Debt/Equity 0.0x
ROE -1,188.2%
ROA -141.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Maia Biotechnology Inc. logo

Maia Biotechnology Inc. (MAIA) Company Overview

About Maia Biotechnology Inc.

What They Do

Develops targeted therapies for cancer treatment.

Business Model

MAIA Biotechnology focuses on the development and commercialization of innovative immuno-oncology drugs. The company generates revenue by bringing its novel therapies, like THIO, through clinical trials and ultimately to market for cancer patients, particularly those with specific genetic markers.

Additional Information

Incorporated in 2018 and based in Chicago, MAIA is dedicated to improving the lives of cancer patients with therapies that target telomerase-positive cancer cells. Its lead product THIO is currently in clinical development, indicating potential growth opportunities for investors.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

13

CEO

Dr. Vlad Vitoc M.B.A., M.D.

Country

United States

IPO Year

2022

Maia Biotechnology Inc. (MAIA) Latest News & Analysis

MAIA stock latest news image
Quick Summary

MAIA Biotechnology reports positive efficacy updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer, indicating potential progress in treatment outcomes.

Why It Matters

Positive efficacy updates from MAIA Biotechnology's trial could indicate potential for FDA approval, impacting stock value and investor interest in biotech sector growth.

Source: Business Wire
Market Sentiment: Neutral
MAIA stock latest news image
Quick Summary

MAIA Biotechnology will present at the Biotech Showcase 2025 in Chicago, highlighting its developments and potential offerings in the biotechnology sector.

Why It Matters

MAIA Biotechnology's presentation at a prominent event like Biotech Showcase 2025 could signal potential growth, attract investor interest, and influence stock performance in the biotech sector.

Source: Business Wire
Market Sentiment: Neutral
MAIA stock latest news image
Quick Summary

MAIA Biotechnology announced that its directors participated in recent private placement closings, indicating insider confidence in the company's financial activities.

Why It Matters

Director participation in private placements signals confidence in the company's future, potentially boosting investor sentiment and impacting stock performance positively.

Source: Business Wire
Market Sentiment: Neutral
MAIA stock latest news image
Quick Summary

MAIA Biotechnology received FDA Rare Pediatric Disease Designation for THIO, aimed at treating pediatric high-grade gliomas.

Why It Matters

FDA designation can enhance THIO's market potential, attract funding, and increase investor confidence in MAIA Biotechnology's growth prospects and future revenues.

Source: Business Wire
Market Sentiment: Neutral
MAIA stock latest news image
Quick Summary

MAIA Biotechnology has announced a private placement to raise approximately $950,000.

Why It Matters

MAIA Biotechnology's $950,000 private placement indicates potential for growth and funding for projects, which could influence stock performance and investor sentiment.

Source: Business Wire
Market Sentiment: Neutral
MAIA stock latest news image
Quick Summary

MAIA Biotechnology has expanded its clinical supply agreement with Regeneron for a Phase 2 trial targeting non-small cell lung cancer.

Why It Matters

The expansion of the clinical supply agreement indicates progress in MAIA's Phase 2 trial, potentially enhancing its market position and attracting investor interest in its oncology pipeline.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About MAIA Stock

What is Maia Biotechnology Inc.'s (MAIA) stock forecast for 2025?

Based on our analysis of 1 Wall Street analysts, Maia Biotechnology Inc. (MAIA) has a median price target of $12.63. The highest price target is $14.00 and the lowest is $11.25.

Is MAIA stock a good investment in 2025?

According to current analyst ratings, MAIA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.87. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MAIA stock?

Wall Street analysts predict MAIA stock could reach $12.63 in the next 12 months. This represents a 575.1% increase from the current price of $1.87. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Maia Biotechnology Inc.'s business model?

MAIA Biotechnology focuses on the development and commercialization of innovative immuno-oncology drugs. The company generates revenue by bringing its novel therapies, like THIO, through clinical trials and ultimately to market for cancer patients, particularly those with specific genetic markers.

What is the highest forecasted price for MAIA Maia Biotechnology Inc.?

The highest price target for MAIA is $14.00 from Robert LeBoyer at Noble Capital Markets, which represents a 648.7% increase from the current price of $1.87.

What is the lowest forecasted price for MAIA Maia Biotechnology Inc.?

The lowest price target for MAIA is $11.25 from at , which represents a 501.6% increase from the current price of $1.87.

What is the overall MAIA consensus from analysts for Maia Biotechnology Inc.?

The overall analyst consensus for MAIA is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.63.

How accurate are MAIA stock price projections?

Stock price projections, including those for Maia Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.